Free shipping on all orders over $ 500

Laquinimod

Cat. No. M1803

All AbMole products are for research use only, cannot be used for human consumption.

Laquinimod Structure
Synonym:

ABR-215062

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
2mg USD 32  USD32 In stock
5mg USD 56  USD56 In stock
10mg USD 88  USD88 In stock
25mg USD 112  USD112 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Laquinimod (ABR-215062) is a new orally active immunoregulator effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. EAE shares important immunological and clinical features with multiple sclerosis (MS). Doses of 16, 1.6 and 0.16 mg/kg/day laquinimod dose-dependently inhibited disease and showed better disease inhibitory effects as compared to roquinimex (Linomide). Furthermore, laquinimod inhibited the inflammation of both CD4+ T cells and macrophages into central nervous tissues, i.e. the spinal cord. It also changed the cytokine balance in favour of TH2/TH3 cytokines IL-4, IL-10 and TGF-beta.

Chemical Information
Molecular Weight 356.8
Formula C19H17ClN2O3
CAS Number 248281-84-7
Solubility (25°C) DMSO 70 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Toubi et al. J Neuroimmunol. Laquinimod modulates B cells and their regulatory effects on T cells in Multiple Sclerosis.

[2] Brück et al. Acta Neuropathol. Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination.

[3] Mishra et al. Am J Pathol. Kinetics of proinflammatory monocytes in a model of multiple sclerosis and its perturbation by laquinimod.

[4] Aharoni et al. J Neuroimmunol. Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis.

Related Immunology/Inflammation Products
Omalizumab

Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) and to membrane-bound form of IgE (mIgE).

Daratumumab

Daratumumab (Daratumumab) is a first-in-class, specific anti-CD38 monoclonal antibody (IgG1). (for human or immunodeficient mice).

Cyclosporine A

Cyclosporine A (CsA,Cyclosporin A) is an immunosuppressant that binds to cyclophilin and inhibits calcineurin with an IC50 of 7 nM. Cyclosporine A [CsA] binds to the cyclophilin 18 (Cyp18)-CsA complex. the Cyp18-CsA complex recruits calcium-regulated neurophosphatase (CaN), leading to the blocking of cytokine gene transcription in activated T cells. CsA is a highly specific inhibitor of T-cell activation.

Pimecrolimus

Pimecrolimus is an immunomodulating agent used in the treatment of atopic dermatitis.

Meloxicam

Meloxicam (Mobic) is a nonsteroidal anti-inflammatory agent with analgesic and fever reducer effects.

  Catalog
Abmole Inhibitor Catalog




Keywords: Laquinimod, ABR-215062 supplier, Immunology/Inflammation, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.